AbbVie Inc. (ABBV) Announces New Data on Venetoclax-Based Combination Therapy

AbbVie Inc. presented new Phase 3 data showing venetoclax plus obinutuzumab significantly improved progression-free survival in chronic lymphocytic leukemia patients compared to chlorambucil and obinutuzumab, with a median follow-up of 9.2 years. Additionally, the European Commission expanded Venclyxto's label for use in combination therapies.

By Jeff Lewis Wed, June 17, 2026 at 8:34 PM GMT+3 2 min read · Yahoo Finance · June 17, 2026, 17:34 UTC

Tickers: $ABBV

Topics: AbbVie CLL14 trial DECNUPAZ European Commission approval FDA approval Venetoclax

Read the full article at Yahoo Finance

More World news

Broadcom and Micron Identified as Top Alternatives to Nvidia Amid Leadership Uncertainty Motley Fool · November 12, 2026, 16:03 UTC
Thomson Reuters Executives to Present at TD Securities Technology Conference PR Newswire · November 12, 2026, 16:00 UTC
BHP to Restructure Australian Iron Ore Operations Amid Rising Costs Seeking Alpha · November 12, 2026, 15:59 UTC
Capri Investment Group and GRIT Chicago Unveil $10 Billion Bronzeville Lakefront Development Plan PR Newswire · November 12, 2026, 16:00 UTC
Whoop Launches 'Whoop Humans' Social Network to Enhance Health Data Sharing TechCrunch · November 12, 2026, 16:00 UTC
SchoolWise Partners Advises on Sale of Wyalusing Valley and Wysox Children's Centers PR Newswire · November 12, 2026, 15:57 UTC
Jensen Huang Resigns as Nvidia CEO Amid Personal Scandal and Leadership Crisis CNBC · November 12, 2026, 15:45 UTC
Keurig Dr Pepper Launches $2 Billion Equity Offering to Reduce Debt Ahead of Corporate Split Seeking Alpha · November 12, 2026, 15:51 UTC
Old National Bancorp Announces Quarterly Dividend of $0.4375 per Share Seeking Alpha · November 12, 2026, 15:53 UTC
Old National Bancorp Announces Quarterly Dividend of $0.4375 per Share Seeking Alpha · November 12, 2026, 15:53 UTC